The overall process of protecting the privacy of data subjects, including clinical study participants, and reducing the risk of re-identification by
- modifying (e.g. suppressing, obscuring, aggregating, altering) identifiable information in structured data and documents
- assessing and controlling the residual risk of re-identification
- considering the context of the data release.
Definition adapted from PHUSE Terminology Harmonisation in Data Sharing and Disclosure Terms and Definitions (version 2) https://advance.phuse.global/pages/viewpage.action?pageId=10878987
Courtesy of TransCelerate project (https://www.transceleratebiopharmainc.com)Case study
